CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 治疗期间桥接治疗不断演变的作用
英文原题：The Evolving Role of Bridging Therapy during CAR-T Therapy.
查看英文原题
The Evolving Role of Bridging Therapy during CAR-T Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 已广泛用于多种血液恶性肿瘤，但患者因素、社会障碍或保险问题可能导致治疗延误。CAR-T 制备周期较长，因此白细胞单采后、输注前给予桥接治疗已成为安全实施治疗的重要环节。本文综述支持桥接治疗的证据、患者选择时需考虑的因素、可用方案及选择依据。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy has gained wide used across an array of hematologic malignancies. Though CAR T therapy has changed outcomes in the treatment of many malignancies its administration can be complicated by delays related to patient-related factors, social barriers, or insurance issues. Because of the lengthy process required to treat a patient with CAR T-cells, bridging therapy (BT), administered after leukapheresis but prior to CAR T infusion, has become an important component of safely administering CAR T therapy.
Here we review data supporting the use of BT, factors to consider in patient selection, and types of available BT and rationale for choosing amongst them.
论文信息
- 作者
- Bhaskar ST、Dholaria B、Savani BN、Oluwole O
- 单位
- Medicine, Hematology and Oncology Vanderbilt University Medical Center.
- 文献类型
- 综述
- 期刊
- Clinical hematology international2024
- 原文标识
- PubMed 39027142 · DOI 10.46989/001c.116261
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →